Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Significant Drop in Short Interest

Key Points

• Zealand Pharma A/S experienced a 31.8% decline in short interest, with a total of 1,388,200 shares short sold as of July 31st.
• Several analysts have upgraded the stock to a "strong-buy" rating, with a consensus rating of "Buy" from research firms.
• In the latest earnings report, the company reported an EPS of $16.06, missing the consensus estimate by ($0.66), with revenue also falling short of expectations.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 1,388,200 shares, adropof31.8% from the July 15th total of 2,034,900 shares. Based on an average trading volume of 600 shares, the short-interest ratio is currently 2,313.7 days. Approximately2.0% of the company's stock are sold short. Approximately2.0% of the company's stock are sold short. Based on an average trading volume of 600 shares, the short-interest ratio is currently 2,313.7 days.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ZLDPF. Wells Fargo & Company raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. BNP Paribas raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Barclays raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. Finally, Zacks Research downgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy".

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF traded up $5.00 on Monday, hitting $66.00. The company's stock had a trading volume of 110 shares, compared to its average volume of 915. Zealand Pharma A/S has a one year low of $49.98 and a one year high of $136.76. The firm has a market capitalization of $4.69 billion, a P/E ratio of 4.63 and a beta of 0.71. The stock has a fifty day moving average of $56.82 and a two-hundred day moving average of $69.35. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing the consensus estimate of $16.72 by ($0.66). Zealand Pharma A/S had a return on equity of 82.30% and a net margin of 73.90%.The business had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $9.18 billion. Research analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.